Only 8 Of The 30 Dow Jones Stocks Were Positive In The First Half Of 2022: Chevron Leads, But Who Else Was Up?

Friday, 1 July 2022, 22:45:49
The U.S. stock market had a rough start to 2022 with a market correction hitting stocks and many indexes seeing their worst performances in decades. What Happened: The S&P 500, as tracked by the SPDR S&P 500 ETF Trust (ARCA:SPY), saw a decline of 20.8% in the first half of 2022. This marked the largest first half decline for the index since 1970. The Dow Jones, which is tracked by the SPDR Dow Jones Industrial Average ETF Trust (ARCA:DIA), ended the first half of the year down 15.5%. The index includes 30 of the country’s largest corporations split among a series of diverse sectors. Here are the eight stocks in the Dow Jones that are positive year-to-date in 2022 through June 30: Chevron Corp (NYSE: CVX ): +23.4% Merck & Co., Inc. (NYSE: MRK ): +19.0% Amgen, Inc. (NASDAQ: Full story available on Benzinga.com
— Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Friday, 1 July 2022, 11:26:22
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. Only one new molecular entity (NME) has been approved thus far in June. NMEs are a key measure of drug innovation as they contain active ingredients yet to be approved by the Food and Drug Administration (FDA). Alnylam Pharmaceutical Inc”s (NASDAQ: ALNY ) RNAi therapeutic Vutrisiran received approval for treating polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Acer Therapeutics Inc (NASDAQ: ACER ) and partner Relief Therapeutics Holding AG (OTC: RLFTF ) received a complete response letter for their urea cycle disorder drug . Bristol-Myers Squibb Co (NYSE: BMY ) received approval for its supplemental biologics license application (sBLA) for Breyanzi for large B-cell lymphoma, while it withdrew its application for Reblozyl as a treatment option for anemia in adults with non-transfusion dependent beta-thalassemia.
— Benzinga

7 Beaten-Down S&P 500 Stocks to Buy Before They Rebound

Thursday, 30 June 2022, 12:00:35
S&P 500 stocks have been a mixed bag at best this year. During the week of June 21, I think the market began to accept the idea that a ” soft landing” by the economy is much more likely than a “hard landing.” Of course, the market rallied during the week. As further evidence of the Street’s renewed optimism, Goldman Sachs economist Jan Hatzius, speaking on Bloomberg TV o n June 24, said that any recession would probably be “on the shallow end.” Even more bullish was RBC Capital Managing Director Gerard Cassidy, who told Bloomberg TV on June 24 that “as long as the job market stays strong, (U.S.) consumers will be in good shape.” 7 REITs to Buy for a Bear Market With the Street realizing that the economy is not going to crash, I believe that there are many good S&P 500 stocks to buy. Meanwhile, as Bloomberg TV’s Lisa Abramowicz pointed out on June 24, many market participants now think that Fed Chairman Jerome Powell will be less “hawkish” on inflation than the Street has generally believed in recent months.
— InvestorPlace

Veterinary Antibiotics Market Set to Witness Explosive Growth by 2022| Zoetis animal healthcare, Merck, Merial (Animal Health Division Of Sanofi)

Thursday, 30 June 2022, 11:33:27
Global Research Report on the Veterinary Antibiotics Market 2022-2030 The collecting, analysis, and interpretation of data obtained from authoritative sources about the Veterinary Antibiotics market from 2022 to 2030 formed the majority of the foundation for the research. The report includes
— OpenPR

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Wednesday, 29 June 2022, 21:27:03
Raymond James initiated coverage on Seagen Inc (NASDAQ: SGEN ) at Outperform with a $220 target price . Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE: MRK ) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable … Full story available on Benzinga.com
— Benzinga